Cantor Fitzgerald Investment Advisors L.P. Makes New Investment in Nutex Health Inc. $NUTX

Key Points

• Cantor Fitzgerald Investment Advisors purchased 10,000 Nutex Health shares worth approximately $2.1 million, acquiring a 0.15% stake. Institutional investors collectively own 5.32% of the company.
• Analyst sentiment remains generally positive: three analysts rate NUTX a Buy and one rates it Hold, producing a “Moderate Buy” consensus and an average price target of $317.50.
• Nutex Health reported quarterly EPS of $9.38, exceeding estimates of $4.95, while revenue reached $210.75 million. Shares opened at $197.61, with the stock trading between $83.99 and $226.16 over the past year.

Cantor Fitzgerald Investment Advisors L.P. purchased a new stake in shares of Nutex Health Inc. (NASDAQ:NUTX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the company's stock, valued at approximately $2,117,000. Cantor Fitzgerald Investment Advisors L.P. owned 0.15% of Nutex Health as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Kilter Group LLC bought a new position in shares of Nutex Health during the second quarter worth about $27,000. Allworth Financial LP bought a new stake in Nutex Health in the 2nd quarter valued at about $35,000. GK Wealth Management LLC bought a new stake in Nutex Health in the 3rd quarter valued at about $73,000. EverSource Wealth Advisors LLC acquired a new position in Nutex Health during the 1st quarter valued at about $83,000. Finally, State of Alaska Department of Revenue boosted its stake in Nutex Health by 243.6% during the 3rd quarter. State of Alaska Department of Revenue now owns 1,000 shares of the company's stock valued at $211,000 after purchasing an additional 709 shares during the period. Institutional investors and hedge funds own 5.32% of the company's stock.

Insider Buying and Selling

In other Nutex Health news, Director Scott Saunders sold 203 shares of the company's stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $214.25, for a total value of $43,492.75. Following the completion of the sale, the director directly owned 400 shares in the company, valued at $85,700. This represents a 33.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 44.68% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have commented on NUTX. B. Riley Financial restated a "buy" rating on shares of Nutex Health in a research report on Friday, September 4th. Zacks Research lowered shares of Nutex Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 6th. Wall Street Zen raised Nutex Health from a "hold" rating to a "buy" rating in a report on Saturday, October 3rd. Weiss Ratings raised Nutex Health from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, October 6th. Finally, Lake Street Capital reiterated a "buy" rating and set a $310.00 price objective (up from $235.00) on shares of Nutex Health in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $317.50.

Nutex Health Price Performance

Shares of NASDAQ NUTX opened at $197.61 on Thursday. The stock has a market cap of $1.35 billion, a P/E ratio of 7.76 and a beta of 0.55. The firm's 50-day simple moving average is $200.58 and its 200 day simple moving average is $161.84. Nutex Health Inc. has a fifty-two week low of $83.99 and a fifty-two week high of $226.16. The company has a quick ratio of 4.96, a current ratio of 5.00 and a debt-to-equity ratio of 0.59.

Nutex Health (NASDAQ:NUTX - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $9.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.95 by $4.43. Nutex Health had a net margin of 21.25% and a return on equity of 39.74%. The firm had revenue of $210.75 million during the quarter, compared to analyst estimates of $215.03 million. Equities analysts expect that Nutex Health Inc. will post 27.58 EPS for the current year.

Nutex Health Company Profile

Nutex Health, Inc NASDAQ: NUTX is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.

Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.

Want to see what other hedge funds are holding NUTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nutex Health Inc. (NASDAQ:NUTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.